Evaluation of Gliomas with Magnetic Resonance Fingerprinting with PET Correlation-A Comparative Study

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 Jun 22

PMID 37345077

Authors

Wolfgang Marik

Pedro Lima Cardoso

Elisabeth Springer

Wolfgang Bogner

Matthias Preusser

Georg Widhalm

Gilbert Hangel

Johannes A Hainfellner

Ivo Rausch

Michael Weber

Victor Schmidbauer

Tatjana Traub-Weidinger

Siegfried Trattnig

Affiliations

Soon will be listed here.

Abstract

Objectives: Advanced MR imaging of brain tumors is still mainly based on qualitative imaging. PET imaging offers additive metabolic information, and MR fingerprinting (MRF) offers a novel approach to quantitative data acquisition. The purpose of this study was to evaluate the ability of MRF to predict tumor regions and grading in combination with PET.

Methods: Seventeen patients with histologically verified infiltrating gliomas and available amino-acid PET data were enrolled. ROIs for solid tumor parts (SPo), perifocal edema (ED1), and normal-appearing white matter (NAWM) were selected on conventional MRI sequences and aligned to the MRF and PET images. The predictability of gliomas by region and grading as well as intermodal correlations were assessed.

Results: For MRF, we calculated an overall predictability by region (SPo, ED1, and NAWM) for all of the MRF parameters of 76.5%, 47.1%, and 94.1%, respectively. The overall ability to distinguish low- from high-grade gliomas using MRF was 88.9% for LGG and 75% for HGG, with an accuracy of 82.4%, a ppV of 85.71%, and an npV of 80%. PET positivity was found in 13/17 patients for solid tumor parts, and in 3/17 patients for the edema region. However, there was no significant difference in region-specific MRF values between PET positive and PET negative patients.

Conclusions: MRF and PET provide quantitative measurements of the tumor tissue characteristics of gliomas, with good predictability. Nonetheless, the results are dissimilar, reflecting the different underlying mechanisms of each method.

Citing Articles

Research Progress on Glioma Microenvironment and Invasiveness Utilizing Advanced Multi-Parametric Quantitative MRI.

Song D, Fan G, Chang M Cancers (Basel). 2025; 17(1.

PMID: 39796702 PMC: 11719598. DOI: 10.3390/cancers17010074.

A Comparison of 7 Tesla MR Spectroscopic Imaging and 3 Tesla MR Fingerprinting for Tumor Localization in Glioma Patients.

Lazen P, Cardoso P, Sharma S, Cadrien C, Roetzer-Pejrimovsky T, Furtner J Cancers (Basel). 2024; 16(5).

PMID: 38473305 PMC: 10931074. DOI: 10.3390/cancers16050943.

Advances in Neuro-Oncological Imaging: An Update on Diagnostic Approach to Brain Tumors.

Sabeghi P, Zarand P, Zargham S, Golestany B, Shariat A, Chang M Cancers (Basel). 2024; 16(3).

PMID: 38339327 PMC: 10854543. DOI: 10.3390/cancers16030576.

References

Ding H, Velasco C, Ye H, Lindner T, Grech-Sollars M, OCallaghan J . Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. Cancers (Basel). 2021; 13(19). PMC: 8507535. DOI: 10.3390/cancers13194742. View

Song S, Shan Y, Wang L, Cheng Y, Yang H, Zhao G . MGMT promoter methylation status shows no effect on [F]FET uptake and CBF in gliomas: a stereotactic image-based histological validation study. Eur Radiol. 2022; 32(8):5577-5587. DOI: 10.1007/s00330-022-08606-9. View

Price S, Jena R, Burnet N, Hutchinson P, Dean A, Pena A . Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006; 27(9):1969-74. PMC: 7977915. View

Lopci E, Riva M, Olivari L, Raneri F, Soffietti R, Piccardo A . Prognostic value of molecular and imaging biomarkers in patients with supratentorial glioma. Eur J Nucl Med Mol Imaging. 2017; 44(7):1155-1164. DOI: 10.1007/s00259-017-3618-3. View

Sebok M, van Niftrik C, Muscas G, Pangalu A, Seystahl K, Weller M . Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration. Neurooncol Adv. 2021; 3(1):vdab048. PMC: 8156976. DOI: 10.1093/noajnl/vdab048. View

Zhang-Yin J, Girard A, Bertaux M . What Does PET Imaging Bring to Neuro-Oncology in 2022? A Review. Cancers (Basel). 2022; 14(4). PMC: 8870476. DOI: 10.3390/cancers14040879. View

Louis D, Perry A, Wesseling P, Brat D, Cree I, Figarella-Branger D . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021; 23(8):1231-1251. PMC: 8328013. DOI: 10.1093/neuonc/noab106. View

Badve C, Yu A, Dastmalchian S, Rogers M, Ma D, Jiang Y . MR Fingerprinting of Adult Brain Tumors: Initial Experience. AJNR Am J Neuroradiol. 2016; 38(3):492-499. PMC: 5352493. DOI: 10.3174/ajnr.A5035. View

Fatouros P, Marmarou A . Use of magnetic resonance imaging for in vivo measurements of water content in human brain: method and normal values. J Neurosurg. 1999; 90(1):109-15. DOI: 10.3171/jns.1999.90.1.0109. View

10.

Palanichamy K, Chakravarti A . Diagnostic and Prognostic Significance of Methionine Uptake and Methionine Positron Emission Tomography Imaging in Gliomas. Front Oncol. 2017; 7:257. PMC: 5672012. DOI: 10.3389/fonc.2017.00257. View

11.

Chung S, Kim D, Breton E, Axel L . Rapid B1+ mapping using a preconditioning RF pulse with TurboFLASH readout. Magn Reson Med. 2010; 64(2):439-46. PMC: 2929762. DOI: 10.1002/mrm.22423. View

12.

Papp L, Potsch N, Grahovac M, Schmidbauer V, Woehrer A, Preusser M . Glioma Survival Prediction with Combined Analysis of In Vivo C-MET PET Features, Ex Vivo Features, and Patient Features by Supervised Machine Learning. J Nucl Med. 2017; 59(6):892-899. DOI: 10.2967/jnumed.117.202267. View

13.

Albert N, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim M . Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro Oncol. 2016; 18(9):1199-208. PMC: 4999003. DOI: 10.1093/neuonc/now058. View

14.

Pirkl C, Nunez-Gonzalez L, Kofler F, Endt S, Grundl L, Golbabaee M . Accelerated 3D whole-brain T1, T2, and proton density mapping: feasibility for clinical glioma MR imaging. Neuroradiology. 2021; 63(11):1831-1851. PMC: 8528802. DOI: 10.1007/s00234-021-02703-0. View

15.

Haubold J, Demircioglu A, Gratz M, Glas M, Wrede K, Sure U . Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric F-FET PET-MRI and MR Fingerprinting. Eur J Nucl Med Mol Imaging. 2019; 47(6):1435-1445. DOI: 10.1007/s00259-019-04602-2. View

16.

Ma D, Gulani V, Seiberlich N, Liu K, Sunshine J, Duerk J . Magnetic resonance fingerprinting. Nature. 2013; 495(7440):187-92. PMC: 3602925. DOI: 10.1038/nature11971. View

17.

Stopa B, Juhasz C, Mittal S . Comparison of Amino Acid PET to Advanced and Emerging MRI Techniques for Neurooncology Imaging: A Systematic Review of the Recent Studies. Mol Imaging. 2021; 2021:8874078. PMC: 8205602. DOI: 10.1155/2021/8874078. View

18.

Tippareddy C, Zhao W, Sunshine J, Griswold M, Ma D, Badve C . Magnetic resonance fingerprinting: an overview. Eur J Nucl Med Mol Imaging. 2021; 48(13):4189-4200. DOI: 10.1007/s00259-021-05384-2. View

19.

Korzdorfer G, Kirsch R, Liu K, Pfeuffer J, Hensel B, Jiang Y . Reproducibility and Repeatability of MR Fingerprinting Relaxometry in the Human Brain. Radiology. 2019; 292(2):429-437. DOI: 10.1148/radiol.2019182360. View

20.

Springer E, Cardoso P, Strasser B, Bogner W, Preusser M, Widhalm G . MR Fingerprinting-A Radiogenomic Marker for Diffuse Gliomas. Cancers (Basel). 2022; 14(3). PMC: 8833555. DOI: 10.3390/cancers14030723. View